Adaptive Radiotherapy for Genitourinary Cancers

Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled

Overview

The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are: Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy? Participants will: Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer (Post Prostatectomy)Bladder Cancer

Interventions

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy; * Age ≥ 18 years; * ECOG performance status score 0-2; * No prior radiotherapy history within the current radiation field; * No contraindications for MRI scanning; * No contraindications for radiotherapy. Exclusion Criteria: * Patients with contraindications to radiotherapy; * Patients unable to tolerate MRI or with contraindications to MRI scanning.

Outcomes

Primary Outcomes

Acute GU and GI toxicities as per NCI-CTC 5.0 criteria 3-months post RT

Time frame: 3-months post-RT

Secondary Outcomes

Quality-of-Life, general

general quality-of-life questionaaires as per EORTC QLQ-C30

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Local control

local control

Time frame: 2-year

disease-free survival

Time frame: 2-year

Late toxicities

Late GU and GI toxicities as per RTOG scales

Time frame: 2-year

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

GU quality-of-life questionaaires as per EORTC QLQ-NMIBC24

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

quality-of-life questionaaires as per EORTC QLQ- BLM30

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

quality-of-life questionaaires as per BCI

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

quality-of-life questionaaires as per FACT-BL

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

quality-of-life questionaaires as per FACT-P

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, GU (genitourinary) and GI (gastrointestinal) scales

quality-of-life questionaaires as per EPIC-26

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Quality-of-Life, sexual scales

quality-of-life questionaaires as per IIEF-5

Time frame: Baseline, 1-month post-RT, every 3 months till 2-years post-RT

Adaptive Radiotherapy for Genitourinary Cancers

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts